%0 Journal Article
%A Bartoletti, Michele
%A Azap, Ozlem
%A Barac, Aleksandra
%A Bussini, Linda
%A Ergonul, Onder
%A Krause, Robert
%A Martin-Quiros, Alejandro
%A Paño-Pardo, José Ramón
%A Power, Nicholas
%A Sibani, Marcella
%A Szabo, Balint Gergely
%A Tsiodras, Sotirios
%A Zollner-Schwetz, Ines
%A Rodríguez-Baño, Jesús
%T European society of clinical microbiology and infectious diseases guidelines for coronavirus disease 2019: an update on treatment of patients with mild/moderate disease.
%D 2022
%U http://hdl.handle.net/10668/22136
%X Despite the large availability of vaccines, coronavirus disease 2019 (COVID-19), induced by severe acute respiratory syndrome coronavirus 2, continues to be a major threat for health-care providers and fragile people. A number of options are now available for outpatients with mild-to-moderate COVID-19 at the risk of disease progression for the prevention of deaths or hospitalization. A European Society of Clinical Microbiology and Infectious Diseases COVID-19 guidelines task force was established by the European Society of Clinical Microbiology and Infectious Diseases Executive Committee. A small group was established, half appointed by the chair and the remaining selected based on an open call. Each panel met virtually once a week. For all decisions, a simple majority vote was used. A long list of clinical questions using the population, intervention, comparison, outcome format was developed at the beginning of the process. For each population, intervention, comparison, outcome, two panel members performed a literature search, with a third panelist involved in case of inconsistent results. Voting was based on the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. In this update, we focus on anti-viral agents, monoclonal antibodies (mAbs) and other treatment options proposed for patients with mild or moderate COVID-19 who are at the risk of hospitalization or death. Although the use of anti-virals is recommended, especially nirmatrelvir/ritonavir and remdesivir or, alternatively, molnupirarvir, the administration of mAbs against the spike protein strictly depends on circulating variants or the ability to test timely for variants and sub-variants. At the time of writing (April-June 2022), the only active mAb was tixagevimab/cilgavimab given the predominance of the Omicron BA.2, BA.3, BA.4 and BA.5 sub-lineages in Europe. However, considering that the epidemiological scenario is extremely dynamic, constant monitoring of variants of concern is mandatory.
%K COVID-19
%K Cilgavimab
%K ESCMID
%K Molnupiravir
%K Nirmatrelvir/ritonavir
%K Outpatients
%K Remdesivir
%K Sotrovimab
%K Tixagevimab
%~